ARGEFAR\u2019dan 46,75 Milyon TL b\u00fct\u00e7eli proje<\/p>\n
Halk sa\u011fl\u0131\u011f\u0131n\u0131 tehdit eden enfeksiyonlara kar\u015f\u0131 tan\u0131 kiti, ila\u00e7 form\u00fclasyonlar\u0131 ve a\u015f\u0131 geli\u015ftirecekler<\/b><\/p>\n
Ege \u00dcniversitesi \u0130la\u00e7 Geli\u015ftirme ve Farmakokinetik Ara\u015ft\u0131rma Uygulama Merkezi (ARGEFAR) y\u00f6neticili\u011finde haz\u0131rlanan \u201c\u00dclkemizde ve D\u00fcnyada Halk Sa\u011fl\u0131\u011f\u0131n\u0131 En Fazla Tehdit Eden HPV ve Influenza Kaynakl\u0131 Enfeksiyonlara Kar\u015f\u0131 Tan\u0131 Kitleri, \u0130la\u00e7 Form\u00fclasyonlar\u0131 ve A\u015f\u0131 Geli\u015ftirilmesi\u201d adl\u0131 proje T\u00dcB\u0130TAK 1004 M\u00fckemmeliyet Merkezi Destekleme Program\u0131 kapsam\u0131nda desteklenmeye uygun bulundu.<\/p>\n
ARGEFAR\u2019\u0131n y\u00f6neticili\u011finde,\u00a0 NOBEL \u0130la\u00e7, \u0130DEA Teknoloji,\u00a0 Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 Halk Sa\u011fl\u0131\u011f\u0131 Genel M\u00fcd\u00fcrl\u00fc\u011f\u00fc Ulusal Viroloji Referans Merkez Laboratuvar\u0131, \u0130zmir Katip \u00c7elebi \u00dcniversitesi, MULT\u0130GEN, FLORAB\u0130O Teknoloji, ABD\u0130 \u0130BRAH\u0130M \u0130la\u00e7, T\u00dcB\u0130TAK \u2013 MAM ortakl\u0131\u011f\u0131nda y\u00fcr\u00fct\u00fclecek olan proje\u00a0 46,75 Milyon TL b\u00fct\u00e7eden olu\u015fuyor. Projenin 21 milyon 611 bin 679 TL pay\u0131 ise Ege \u00dcniversitesine ayr\u0131ld\u0131.<\/p>\n
Ege \u00dcniversitesi Rekt\u00f6r\u00fc Prof. Dr. Necdet Budak, \u201c\u00dcniversitemiz akademisyenleri ve ara\u015ft\u0131rmac\u0131lar\u0131 taraf\u0131ndan haz\u0131rlanan projeler ulusal ve uluslararas\u0131 ajanslar ve kurulu\u015flar taraf\u0131ndan desteklenmeye devam ediyor. Son y\u0131llarda olu\u015fturdu\u011fumuz ara\u015ft\u0131rma k\u00fclt\u00fcr\u00fc ve giri\u015fimcilik ekosistemi ile\u00a0 model olu\u015fturan \u00fcniversitemizin \u00f6nc\u00fcl\u00fc\u011f\u00fcnde ve y\u00fcr\u00fct\u00fcc\u00fcl\u00fc\u011f\u00fcnde\u00a0 \u00f6nemli projeler haz\u0131rlan\u0131yor. Multisipliner ve i\u015f birli\u011fine dayanan bu \u00e7al\u0131\u015fmalar\u0131m\u0131z ulusal ve uluslararas\u0131 kurulu\u015flar taraf\u0131ndan \u00f6nemli destekler alarak hem bilime hem de insanl\u0131\u011fa katk\u0131 yapan nitelikli projelere d\u00f6n\u00fc\u015f\u00fcyor. Yeni tip koronavir\u00fcs (Covid-19) hastal\u0131\u011f\u0131na y\u00f6nelik Milli A\u015f\u0131 \u00e7al\u0131\u015fmalar\u0131na \u00f6nc\u00fcl\u00fck eden ARGEFAR, b\u00fcnyesinde yer alan laboratuvar ve klinikler arac\u0131l\u0131\u011f\u0131yla halk sa\u011fl\u0131\u011f\u0131n\u0131n korunmas\u0131na ve iyile\u015ftirilmesine y\u00f6nelik g\u0131da, \u00e7evre ve ila\u00e7 alanlar\u0131nda \u00f6nemli analiz hizmetleri veriyor.\u00a0 Bilim insanlar\u0131 ARGEFAR y\u00f6neticili\u011finde \u00f6nemli bir projeye daha imza att\u0131lar. \u00dclkemizde ve d\u00fcnyada halk sa\u011fl\u0131\u011f\u0131n\u0131 en fazla tehdit eden HPV ve \u0131nfluenza kaynakl\u0131 enfeksiyonlara kar\u015f\u0131 tan\u0131 kitleri, ila\u00e7 form\u00fclasyonlar\u0131 ve a\u015f\u0131 geli\u015ftirilmesine y\u00f6nelik \u00e7al\u0131\u015fmalar ger\u00e7ekle\u015ftirecekler. T\u00dcB\u0130TAK M\u00fckemmeliyet Merkezi Destekleme Program\u0131 kapsam\u0131nda fonlanacak projede eme\u011fi ge\u00e7en bilim insanlar\u0131n\u0131 tebrik ediyor, ba\u015far\u0131lar\u0131n\u0131n devam\u0131n\u0131 diliyorum\u201d dedi.<\/p>\n
\u201cARGEFAR \u00f6nemli bilimsel birikime ve tecr\u00fcbeye sahip\u201d<\/b><\/p>\n
Projenin detaylar\u0131 ile ilgili bilgiler payla\u015fan E\u00dc \u0130la\u00e7 Geli\u015ftirme ve Farmakokinetik Ara\u015ft\u0131rma – Uygulama Merkezi M\u00fcd\u00fcr V. Prof. Dr. Erc\u00fcment Karasulu, \u201cT\u00dcB\u0130TAK 1004 M\u00fckemmeliyet Merkezi Destekleme Program\u0131n\u0131n amac\u0131; y\u00fcksek\u00f6\u011fretim kurumlar\u0131 ara\u015ft\u0131rma altyap\u0131lar\u0131n\u0131n, Ar-Ge\/tasar\u0131m merkezleri ve kamu Ar- Ge birimleri ile i\u015f birli\u011fi yaparak ihtisasla\u015fmas\u0131 ve m\u00fckemmeliyet merkezi haline gelmesi i\u00e7in ulusal hedef ve politikalar kapsam\u0131nda belirlenen \u00f6ncelikli alanlarda, yurt i\u00e7inde yap\u0131lan, izlenebilir hedefleri olan, bilimsel nitelikli, ticarile\u015fme potansiyeli y\u00fcksek ara\u015ft\u0131rma programlar\u0131n\u0131 desteklemektir. Bu proje ile toplum sa\u011fl\u0131\u011f\u0131 a\u00e7\u0131s\u0131ndan \u00fclkemizde ve d\u00fcnyada \u00e7ok \u00f6nemli bir problem olan, s\u0131k g\u00f6zlenen viral enfeksiyon hastal\u0131klar\u0131na kar\u015f\u0131 \u2018Tan\u0131 Kitleri, \u0130la\u00e7 Form\u00fclasyonlar\u0131 ve A\u015f\u0131 Geli\u015ftirilmesi\u2019 hedefleniyor. \u00a0Bu odak alan\u0131n se\u00e7ilmesinde ba\u015fl\u0131ca sebep ARGEFAR ve konsorsiyum ortaklar\u0131n\u0131n bu alandaki \u00f6nemli bilimsel birikim ve tecr\u00fcbeye sahip olmas\u0131d\u0131r\u201d diye konu\u015ftu.<\/p>\n
\u201cProje 3 farkl\u0131 odak alanda ilerleyecek\u201d<\/b><\/p>\n
Proje kapsam\u0131nda ger\u00e7ekle\u015ftirilecek olan kritik ileri teknoloji hedeflerinden bahseden Prof. Dr. Karasulu, \u201c\u00dclkemizde ve d\u00fcnyada halk sa\u011fl\u0131\u011f\u0131n\u0131 tehdit eden kritik \u00f6neme sahip human papilloma vir\u00fcs (HPV) ve influenza vir\u00fcs\u00fcn\u00fcn yaratt\u0131\u011f\u0131 hastal\u0131klar\u0131n tan\u0131s\u0131, tedavisi ve bu hastal\u0131klardan korunma ve tedavisine y\u00f6nelik a\u015f\u0131 ve ila\u00e7 form\u00fclasyonlar\u0131n\u0131n geli\u015ftirilmesi yan\u0131nda bu hastal\u0131k etkenlerinin tan\u0131s\u0131n\u0131 y\u00fcksek duyarl\u0131l\u0131k ve \u00f6zg\u00fcll\u00fckte sa\u011flayacak ve ayn\u0131 zamanda vir\u00fcs-konak\u00e7\u0131 etkile\u015fimlerini de saptayabilecek tan\u0131 kitlerinin geli\u015ftirilmesidir. Sunulan proje hem \u00fclkemizde hem de d\u00fcnyada sa\u011fl\u0131k sistemi \u00fczerinde \u00e7ok ciddi y\u00fck\u00fc bulunan ve s\u0131k g\u00f6zlenen 2 viral enfeksiyon hastal\u0131\u011f\u0131na (HPV ve Influenza) kar\u015f\u0131 b\u00fct\u00fcnc\u00fcl yakla\u015f\u0131m sergileyecek ve birbirleriyle s\u0131k\u0131 s\u0131k\u0131ya ili\u015fkide olan 3 farkl\u0131 odak alanda ilerleyecektir. Birincisi Tan\u0131 Grubu\u2019dur.\u00a0 Bahsedilen vir\u00fcslerin tan\u0131s\u0131n\u0131 ger\u00e7ekle\u015ftirmek i\u00e7in biyosens\u00f6r ve genetik tabanl\u0131 y\u00f6ntemler kullanacaklard\u0131r. Genetik tabanl\u0131 y\u00f6ntemler ayn\u0131 zamanda d\u00fcnyada ilk defa konak\u00e7\u0131 geneti\u011fi ile ilgili de ger\u00e7ekle\u015ftirecektir. Projede t\u00fcm deneyleri entegre eden biyoinformatik bir yakla\u015f\u0131mla yaz\u0131l\u0131mlar geli\u015ftirilecek, ileri d\u00fczey biyoinformatik analizlerin tamam\u0131n\u0131n son kullan\u0131c\u0131n\u0131n bu konuda zorluk ya\u015famas\u0131na izin vermeyecek ve basit bir \u015fekilde test sonucunu haz\u0131rlamas\u0131 sa\u011flanacakt\u0131r.\u00a0 \u0130kincisi \u0130la\u00e7 Formulasyonu Grubu\u2019dur. HPV ve Influenza tedavisinde etkin, inhaler\/nazal form\u00fclasyonlar, a\u011f\u0131zda da\u011f\u0131lan tablet form\u00fclasyonlar\u0131, jel ve transdermal yama form\u00fclasyonlar\u0131 geli\u015ftirilmesi planlanmaktad\u0131r. S\u00f6z konusu form\u00fclasyonlar\u0131n, karaci\u011ferden ilk ge\u00e7i\u015f etkisini \u00f6nlemesi, \u00f6zellikle ya\u015fl\u0131 ve \u00e7ocuklar gibi ila\u00e7 al\u0131m\u0131nda g\u00fc\u00e7l\u00fck \u00e7eken hastalar i\u00e7in kolay ila\u00e7 al\u0131m\u0131na olanak sa\u011flamas\u0131, ilac\u0131n terap\u00f6tik etkinli\u011fini art\u0131rmas\u0131, yan etkisini azaltmas\u0131 ve hastan\u0131n ya\u015fam kalitesini art\u0131rmas\u0131 ama\u00e7lanmaktad\u0131r. Bu nedenle \u00f6nerilen form\u00fclasyonlar\u0131n piyasada var olanlara alternatif olarak yenilik\u00e7i bir bak\u0131\u015f a\u00e7\u0131s\u0131yla toplum sa\u011fl\u0131\u011f\u0131na sunulmas\u0131 hedeflenmektedir. \u00dc\u00e7\u00fcnc\u00fcs\u00fc ise A\u015f\u0131 Grubu\u2019dur. \u00a0Yurdumuzda ve d\u00fcnyada influenza vir\u00fcslerine kar\u015f\u0131 etkili ilk defa yerli ve milli polivalan DNA ve rekombinant protein a\u015f\u0131lar\u0131 yan\u0131nda, inaktif influenza a\u015f\u0131 form\u00fclasyonlar\u0131n\u0131n geli\u015ftirilmesi ama\u00e7lanmaktad\u0131r. Piyasada bulunan influenza a\u015f\u0131lar\u0131n\u0131n yurdumuzda bulunan alt tipleri kapsamamas\u0131 yan\u0131nda pandemik grip salg\u0131n\u0131na kar\u015f\u0131 ani geli\u015ftirilebilecek bir a\u015f\u0131 geli\u015ftirme platformumuzun olmamas\u0131 bu projede geli\u015ftirilecek a\u015f\u0131lar\u0131n stratejik ve yenilik\u00e7i y\u00f6n\u00fcn\u00fc ortaya \u00e7\u0131karmaktad\u0131r\u201d dedi.<\/p>\n","protected":false},"excerpt":{"rendered":"
ARGEFAR\u2019dan 46,75 Milyon TL b\u00fct\u00e7eli proje Halk sa\u011fl\u0131\u011f\u0131n\u0131 tehdit eden enfeksiyonlara kar\u015f\u0131 tan\u0131 kiti, ila\u00e7…<\/p>\n","protected":false},"author":2,"featured_media":3630,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-3629","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-gncl"],"featured_image_urls":{"full":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2021\/05\/EGE-ARGEFAR-1004-PROJE-scaled.jpg",2560,1707,false],"thumbnail":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2021\/05\/EGE-ARGEFAR-1004-PROJE-150x150.jpg",150,150,true],"medium":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2021\/05\/EGE-ARGEFAR-1004-PROJE-300x200.jpg",300,200,true],"medium_large":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2021\/05\/EGE-ARGEFAR-1004-PROJE-768x512.jpg",640,427,true],"large":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2021\/05\/EGE-ARGEFAR-1004-PROJE-1024x683.jpg",640,427,true],"1536x1536":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2021\/05\/EGE-ARGEFAR-1004-PROJE-1536x1024.jpg",1536,1024,true],"2048x2048":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2021\/05\/EGE-ARGEFAR-1004-PROJE-2048x1365.jpg",2048,1365,true],"newsphere-slider-full":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2021\/05\/EGE-ARGEFAR-1004-PROJE-1280x720.jpg",1280,720,true],"newsphere-featured":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2021\/05\/EGE-ARGEFAR-1004-PROJE-1024x683.jpg",1024,683,true],"newsphere-medium":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2021\/05\/EGE-ARGEFAR-1004-PROJE-720x380.jpg",720,380,true]},"author_info":{"display_name":"Editor","author_link":"https:\/\/www.euegeajans.com\/index.php\/author\/editor\/"},"category_info":"G\u00fcncel<\/a>","tag_info":"G\u00fcncel","comment_count":"0","_links":{"self":[{"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/posts\/3629","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/comments?post=3629"}],"version-history":[{"count":1,"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/posts\/3629\/revisions"}],"predecessor-version":[{"id":3631,"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/posts\/3629\/revisions\/3631"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/media\/3630"}],"wp:attachment":[{"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/media?parent=3629"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/categories?post=3629"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/tags?post=3629"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}